Makary Signals Support For Biosimilar Interchangeability Reform

By Maaisha Osman / May 22, 2025 at 6:20 PM

FDA Commissioner Marty Makary signaled his support to streamline the approval and uptake of biosimilar drugs in his first appearance before Congress as commissioner Thursday (May 22), including reconsideration of removing the controversial "interchangeability" designation that industry experts say has hindered competition and kept drug prices high.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.